

Servier Medical Art is licensed under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) 

This license requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, even for commercial purposes. [More info](https://creativecommons.org/licenses/by/4.0/)

SERVIER MEDICAL ART

A service to medicine provided by Les Laboratoires Servier
www.servier.com



Figure 1 Schematic representation of the immunometabolic crosstalk in the gut-liver axis linking inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease. The diagram illustrates three critical mechanisms: (1) Dysbiosis: In the inflammatory bowel disease gut, dysbiosis leads to the production of pathogenic metabolites (*e.g.*, trimethylamine N-oxide, endogenous ethanol) and a functional downregulation of short-chain fatty acid receptors (G protein-coupled receptors 41 and 43), creating a pro-inflammatory environment; (2) Pathogenic Th17: An interleukin-23-rich milieu promotes the differentiation of pathogenic Th17 cells. This axis can be therapeutically targeted by the interleukin-23 inhibitor Guselkumab; and (3) Sphingosine-1-phosphate modulation: Sphingosine-1-phosphate receptor modulators, such as Etrasimod, prevent lymphocyte egress from lymphoid tissues, thereby reducing immune cell infiltration into the liver. Center (gut-liver crosstalk): These metabolites and immune cells translocate *via* the portal vein to the liver, driving hepatic inflammation and steatosis. Parts of this figure were adapted from Servier Medical Art (<https://smart.servier.com/>), licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) (Supplementary material). GPR: G protein-coupled receptors; S1P: Sphingosine-1-phosphate; TMAO: Trimethylamine N-oxide.